RiceBran Technologies (RIBT) 10-Q 5 May 20 2020 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2020	Apr. 27, 2020
Cover [Abstract]
Entity Registrant Name	RiceBran Technologies
Entity Central Index Key	0001063537
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Shell Company	false
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Common Stock, Shares Outstanding		40,097,517
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q1
Entity Address, State or Province	TX

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Condensed Consolidated Statements of Operations (Unaudited) [Abstract]
Revenues	$ 8,330	$ 6,364
Cost of goods sold	8,735	6,021
Gross profit (loss)	(405)	343
Selling, general and administrative expenses	2,550	3,341
Operating loss	(2,955)	(2,998)
Interest income	11	0
Interest expense	(49)	(12)
Other expense	(45)	(1)
Other income	5	0
Loss before income taxes	(3,033)	(3,011)
Income tax benefit	0	0
Loss from continuing operations	(3,033)	(3,011)
Loss from discontinued operations	0	(216)
Net loss	$ (3,033)	$ (3,227)
Basic loss per common share:
Continuing operations (in dollars per share)	$ (0.08)	$ (0.10)
Discontinued operations (in dollars per share)	0	(0.01)
Basic loss per common share (in dollars per share)	(0.08)	(0.11)
Diluted loss per common share:
Continuing operations (in dollars per share)	(0.08)	(0.10)
Discontinued operations (in dollars per share)	0	(0.01)
Diluted loss per common share (in dollars per share)	$ (0.08)	$ (0.11)
Weighted average number of shares outstanding:
Basic (in shares)	39,963,155	29,347,318
Diluted (in shares)	39,963,155	29,347,318

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 5,517	$ 8,444
Accounts receivable, net of allowance for doubtful accounts of $50 and $347	5,106	3,738
Inventories	1,916	898
Other current assets	894	691
Total current assets	13,433	13,771
Property and equipment, net	18,769	19,077
Operating lease right-of-use assets	2,678	2,752
Goodwill	3,915	3,915
Intangible assets	890	950
Other long-term assets	0	27
Total assets	39,685	40,492
Current liabilities:
Accounts payable	1,146	833
Commodities payable	1,937	829
Accrued salary, wages and benefits	1,051	877
Accrued expenses	690	884
Customer prepayments	0	12
Operating lease liabilities, current portion	316	309
Due under insurance premium finance agreements	314	116
Finance lease liabilities, current portion	102	101
Due under factoring agreement	2,306	1,823
Long-term debt, current portion	29	28
Total current liabilities	7,891	5,812
Operating lease liabilities, less current portion	2,543	2,674
Finance lease liabilities, less current portion	164	190
Long-term debt, less current portion	65	73
Total liabilities	10,663	8,749
Commitments and contingencies
Shareholders' equity:
Common stock, no par value, 50,000,000 shares authorized, 40,092,197 shares and 40,074,483 shares, issued and outstanding	319,123	318,811
Accumulated deficit	(290,213)	(287,180)
Total shareholders' equity	29,022	31,743
Total liabilities and shareholders' equity	39,685	40,492
Series G Convertible Preferred Stock [Member]
Shareholders' equity:
Preferred stock, 20,000,000 shares authorized: Series G, convertible, 3,000 shares authorized, stated value $225, 225 shares, issued and outstanding	$ 112	$ 112

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Current assets:
Accounts receivable, allowance for doubtful accounts	$ 50	$ 347
Shareholders' equity:
Preferred stock, shares authorized (in shares)	20,000,000	20,000,000
Common stock, par value (in dollars per share)	$ 0	$ 0
Common stock, shares authorized (in shares)	50,000,000	50,000,000
Common stock, shares issued (in shares)	40,092,197	40,074,483
Common stock, shares outstanding (in shares)	40,092,197	40,074,483
Series G Convertible Preferred Stock [Member]
Shareholders' equity:
Preferred stock, shares authorized (in shares)	3,000	3,000
Preferred stock, stated value	$ 225	$ 225
Convertible preferred stock, shares issued (in shares)	225	225
Convertible preferred stock, shares outstanding (in shares)	225	225

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Cash flow from operating activities:
Net loss	$ (3,033)	$ (3,227)
Loss from discontinued operations	0	216
Loss from continuing operations	(3,033)	(3,011)
Adjustments to reconcile net loss from continuing operations to net cash used in operating activities:
Depreciation	579	408
Amortization	59	2
Stock and share-based compensation	312	392
Other	(79)	(48)
Changes in operating assets and liabilities, net of impact of acquisitions:
Accounts receivable	(1,315)	(1,244)
Inventories	(1,018)	(149)
Accounts payable and accrued expenses	231	(294)
Commodities payable	1,108	(1,818)
Other	(178)	(359)
Net cash used in operating activities	(3,334)	(6,121)
Cash flows from investing activities:
Purchases of property and equipment	(221)	(1,160)
Net cash used in investing activities	(221)	(1,160)
Cash flows from financing activities:
Payments on factoring agreement	(6,995)	0
Advances on factoring agreement	7,455	0
Advances on insurance premium finance agreements	344	272
Payments on insurance premium finance agreements	(144)	(112)
Payments of debt and finance lease liabilities	(32)	(278)
Proceeds from issuance of common stock and pre-funded warrant, net of issuance costs	0	11,593
Proceeds from common stock warrant exercises	0	1,980
Proceeds from common stock option exercises	0	60
Net cash provided by financing activities	628	13,515
Net change in cash and cash equivalents and restricted cash	(2,927)	6,234
Cash and cash equivalents and restricted cash, beginning of period
Cash and cash equivalents	8,444	7,044
Restricted cash	0	225
Cash and cash equivalents and restricted cash, beginning of period	8,444	7,269
Cash and cash equivalents and restricted cash, end of period
Cash and cash equivalents	5,517	13,278
Restricted cash	0	225
Cash and cash equivalents and restricted cash, end of period	5,517	13,503
Supplemental disclosures:
Cash paid for interest	26	12
Cash paid for income taxes	$ 0	$ 0

BASIS OF PRESENTATION

BASIS OF PRESENTATION	3 Months Ended
	Mar. 31, 2020
BASIS OF PRESENTATION [Abstract]
BASIS OF PRESENTATION	NOTE 1. BASIS OF PRESENTATION In the opinion of management, the accompanying unaudited condensed consolidated financial statements (interim financial statements) of RiceBran Technologies and its subsidiaries were prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) and the rules and regulations of the Securities and Exchange Commission (SEC) for reporting on Form 10-Q; therefore, they do not include all of the information and notes required by GAAP for complete financial statements. The interim financial statements contain all adjustments necessary to present fairly the interim results of operations, financial position and cash flows for the periods presented of a normal and recurring nature necessary to present fairly the interim results of operations, financial position and cash flows for the periods presented. These interim financial statements should be read in conjunction with the consolidated audited financial statements and notes thereto in our Annual Report on Form 10-K for the year ended December 31, 2019, which included all disclosures required by generally accepted accounting principles. The results reported in these interim financial statements are not necessarily indicative of the results to be expected for the full fiscal year, or any other future period, and have been prepared based on the realization of assets and the satisfaction of liabilities in the normal course of business.

BUSINESS

BUSINESS	3 Months Ended
	Mar. 31, 2020
BUSINESS [Abstract]
BUSINESS	NOTE 2. BUSINESS We are a specialty ingredient company focused on producing value-added processing and marketing of healthy, natural and nutrient dense products derived from rice and other small grains, and the by-products created in the milling of these grains. Notably, we apply our proprietary technologies to convert raw rice bran into stabilized rice bran (SRB), and high value derivative products including: RiBalance, a rice bran nutritional package derived from SRB; RiSolubles, a nutritious, carbohydrate and lipid rich fraction of RiBalance; RiFiber, a fiber rich insoluble derivative of RiBalance and ProRyza, a rice bran protein-based product; and a variety of other valuable derivatives extracted from these core products. In granular form, SRB is a food additive used in the production of products for both human and animal consumption. We believe SRB has certain inherent qualities that make it more attractive for this purpose than food additives based on the by-products of other agricultural commodities, such as corn and soybeans. Our SRB and refined SRB products and derivatives support the production of healthy, natural, hypoallergenic, gluten free, and non-genetically modified ingredients and supplements for use in meats, baked goods, cereals, coatings, health foods, and high-end animal nutrition. Our target customers are natural food, food and animal nutrition manufacturers, wholesalers and retailers, both domestically and internationally. We manufacture and distribute SRB in various granulations from four locations: two leased facilities located within supplier-owned rice mills in Arbuckle and West Sacramento, California; one company-owned facility in Mermentau, Louisiana; and our company-owned rice mill in Wynne, Arkansas. At our Dillon, Montana facility, we produce SRB based products and derivatives that have been further refined through our proprietary processes. Our rice mill in Wynne, Arkansas also supplies grades U.S. No. 1 and No. 2 premium long and medium white rice. In April 2019, we purchased a grain processing facility in East Grand Forks, Minnesota, to expand the variety of grains which we can offer to the market.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	3 Months Ended
	Mar. 31, 2020
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Recent Accounting Guidance Recent accounting standards not yet adopted The following discusses the accounting standard(s) not yet adopted that will, or are expected to, result in a significant change in practice and/or have a significant financial impact on us. In June 2016, the Financial Accounting Standards Board (FASB) issued guidance ASU No. 2016-13 Financial Instruments—Credit Losses (Topic 326) Measurement of Credit Losses on Financial Instruments Recently adopted accounting standards In December 2019, the FASB issued guidance ASU No. 2019-12 - Income Taxes implifying the Accounting for Income Taxes Reclassifications

ACQUISITION

ACQUISITION	3 Months Ended
	Mar. 31, 2020
ACQUISITION [Abstract]
ACQUISITION	NOTE 4. ACQUISITION On April 4, 2019, we acquired substantially all of the assets comprising the business of MGI Grain Processing, LLC, a Minnesota limited liability company, now conducting business as MGI Grain Incorporated (MGI) 2019. The following table provides unaudited pro forma information for the three months ended March 31, 2019, as if the MGI acquisition had occurred January 1, 2019. Revenues (in thousands) $ 7,506 Loss from continuing operations (in thousands) $ (2,736 ) Loss per share - continuing operations $ (0.09 ) Weighted average number of common shares outstanding - basic and diluted 29,347,318 No adjustments have been made in the pro forma information for synergies that are resulting or planned from the MGI acquisition. The unaudited proforma information is not indicative of the results that may have been achieved had the companies been combined as of January 1, 2018, or of our future operating results

CASH AND CASH EQUIVALENTS

CASH AND CASH EQUIVALENTS	3 Months Ended
	Mar. 31, 2020
CASH AND CASH EQUIVALENTS [Abstract]
CASH AND CASH EQUIVALENTS	NOTE 5. CASH AND CASH EQUIVALENTS As of March 31, 2020, we have $4.0 million of cash and cash equivalents invested in a money market fund with net assets invested in U.S. Dollar denominated money market securities of domestic and foreign issuers, U.S. Government securities and repurchase agreements. We consider all liquid investments with original maturities of three months or less at the time of purchase to be cash equivalents. We have cash on deposit in excess of federally insured limits at a bank. We do not believe that maintaining substantially all such assets with the bank or investing in a liquid mutual fund represent material risks.

ACCOUNTS RECEIVABLE AND REVENUE

ACCOUNTS RECEIVABLE AND REVENUES	3 Months Ended
	Mar. 31, 2020
ACCOUNTS RECEIVABLE AND REVENUES [Abstract]
ACCOUNTS RECEIVABLE AND REVENUES	NOTE 6. ACCOUNTS RECEIVABLE AND REVENUES Amounts billed and due from our customers are classified as accounts receivables on our consolidated balance sheets and require payment on a short-term basis. owever certain customers have terms of up to 120 days. For substantially all of our contracts, control of the ordered product(s) transfers at our location. consolidated Revenues in the three months ended March 31, 2020, include less than $0.1 million in unearned revenue as of December 31, 2019. Our accounts receivable potentially subject us to significant concentrations of credit risk. Revenues and accounts receivable from significant customers (customers with revenue or accounts receivable in excess of 10% of consolidated totals) are stated below as a percent of consolidated totals. Customer A B C D % of revenue, three months ended March 31, 2020 8 % 17 % 8 % 2 % % of revenue, three months ended March 31, 2019 10 % 18 % 10 % - % % of accounts receivable, as of March 31, 2020 9 % 25 % 13 % 4 % % of accounts receivable, as of December 31, 2019 10 % 31 % - % 10 % In all periods presented, less than 10% of our revenues related to shipments to locations outside of the U.S. T Three Months Ended March 31, 2020 2019 Food $ 6,192 $ 4,747 Animal nutrition 2,138 1,617 Revenues $ 8,330 $ 6,364

INVENTORIES

INVENTORIES	3 Months Ended
	Mar. 31, 2020
INVENTORIES [Abstract]
INVENTORIES	NOTE 7. INVENTORIES The following table details the components of inventories (in thousands). March 31, December 31, Finished goods $ 1,763 $ 698 Raw materials 20 90 Packaging 133 110 Inventories $ 1,916 $ 898

LEASES

LEASES	3 Months Ended
	Mar. 31, 2020
LEASES [Abstract]
LEASES	NOTE 8. LEASES The components of lease expense and cash flows from leases (amounts in thousands) follow. Three Months Ended March 31, 2020 2019 Finance lease cost: Amortization of right-of use assets, included in cost of goods sold $ 21 $ 4 Interest on lease liabilities 4 2 Operating lease cost, included in selling, general and administrative expenses: Fixed leases cost 130 130 Variable lease cost 15 32 Short-term lease cost 3 9 Total lease cost $ 173 $ 177 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from finance leases $ 4 $ 2 Operating cash flows from operating leases $ 130 $ 130 Financing cash flows from finance leases $ 26 $ 11 As of March 31, 2020, variable lease payments do not depend on a rate or index. As of March 31, 2020, property and equipment, net, million of finance lease right-of-use-assets, with an original cost of $0.4 million. As of March 31, 2020, we do not believe it is certain that we will exercise any renewal options. The remaining terms of our leases and the discount rates used in the calculation of the fair value of our leases as of March 31, 2020, follows. Operating Leases Finance Leases Remaining leases terms (in years) 3.6-12.9 0.8-4.3 Weighted average remaining lease terms (in years) 7.5 3.1 Discount rates 6.3%-9.0 % 4.3%-6.0 % Weighted average discount rate 7.6 % 5.8 % Maturities of lease liabilities as of March 31, 2020, follows (in thousands). Operating Finance 2020 (nine months ended December 31, 2020) 346 85 2021 536 91 2022 548 68 2023 528 38 2024 428 11 Thereafter 1,469 - Total lease payments 3,855 293 Amounts representing interest (996 ) (27 ) Present value of lease obligations $ 2,859 $ 266

DEBT

DEBT	3 Months Ended
	Mar. 31, 2020
DEBT [Abstract]
DEBT	NOTE 9. DEBT In the three months ended March 31, 2020, we financed amounts owed for annual insurance premiums under financing agreements, due in monthly installments of principal and interest though November 2020, at interest rates of 4.7% to 5.5% per year. In October 2019, we entered into a factoring agreement which provides for a $7.0 million credit facility with a lender. We may only borrow to the extent we have qualifying accounts receivable as defined in the agreement. The facility has an initial two-year term and automatically renews for successive annual periods, unless proper termination notice is given. We paid a $0.2 million facility fee upon inception of the agreement which is amortizing to interest expense on a straight-line basis over two years. We incur recurring fees under the agreement, including a funding fee of 0.5% above the prime rate, in no event to be less than 5.5%, on any advances and a service fee on average net funds borrowed. During the three months ended March 31, 2020, we expensed $0.1 million of interest and fees under the agreement, fees incurred averaged 3.9% (exclusive of deferred cost amortization) and interest averaged 1.7% of the amounts outstanding under the facility. During the three months ended March 31, 2020, outstanding borrowings under the agreement averaged $1.1 million per day. Amortization of debt issuance costs in the three months ended March 31, 2020, was less than $0.1 million. The lender has the right to demand repayment of the advances at any time. The lender has a security interest in personal property assets. Due under factoring agreement consists of the following (in thousands). March 31, 2020 December 31, Borrowings outstanding $ 2,449 $ 1,989 Debt issuance costs, net (143 ) (166 ) Due under factoring agreement $ 2,306 $ 1,823 Long-term debt consists of the following (in thousands). March 31, December 31, Equipment notes - Initially recorded in November 2018, in the acquisition of Golden Ridge, at the present value of future payments using a discount rate of 4.8%, which we determined approximated the market rate for similar debt with similar maturities as of the date of acquisition. Payable in monthly installments. Expire at dates ranging through 2022. $ 56 $ 62 Equipment note - Dated December 2019. Due in monthly installments through December 2024. Interest accrues at the effective discount rate of 9.3%. 38 39 Total long term debt $ 94 $ 101

EQUITY, SHARE-BASED COMPENSATIO

EQUITY, SHARE-BASED COMPENSATION AND WARRANTS	3 Months Ended
	Mar. 31, 2020
EQUITY, SHARE-BASED COMPENSATION AND WARRANTS [Abstract]
EQUITY, SHARE-BASED COMPENSATION AND WARRANTS	NOT E 10. EQUITY, SHARE-BASED COMPENSATION AND WARRANTS A summary of equity activity for the three months ended March 31, 2020 and March 31, 2019, follows (in thousands, except share amounts). Shares Preferred Series G Common Preferred Stock Common Accumulated Equity Balance, December 31, 2019 225 40,074,483 $ 112 $ 318,811 $ (287,180 ) $ 31,743 Common stock awards under equity incentive plans - 17,534 - 312 - 312 Net loss - - - - (3,033 ) (3,033 ) Balance, March 31, 2020 225 40,092,017 $ 112 $ 319,123 $ (290,213 ) $ 29,022 Shares Preferred Common Preferred Common Stock Accumulated Equity Balance, December 31, 2018 405 29,098,207 $ 201 $ 296,739 $ (273,229 ) $ 23,711 Proceeds from sale of common stock and prefunded warrant, net of costs - 3,046,668 - 11,593 - 11,593 Common stock awards under equity incentive plans - 36,881 - 364 - 364 Exercise of common stock warrants - 600,000 - 1,980 - 1,980 Conversion of preferred stock into common stock (180 ) 170,818 (89 ) 89 - - Exercise of common stock options - 77,078 - 60 - 60 Other - - - 28 - 28 Net loss - - - - (3,227 ) (3,227 ) Balance, March 31, 2019 225 33,029,652 $ 112 $ 310,853 $ (276,456 ) $ 34,509 On March 30, 2020, we entered into an at market issuance sales agreement with respect to an at-the-market offering program, under which we may offer and sell shares of our common stock having an aggregate offering price of up to $6.0 million through B. Riley FBR, Inc, as sales agent. The issuance and sale, if any, of our common stock under the agreement will be made pursuant to our effective “shelf” registration statement on Form S-3. Share-based compensation by type of award for the three months ended March 31, 2020, follows (in thousands). Common stock, vested at issuance and nonvested at issuance $ 105 Stock options 85 Restricted stock units 122 Compensation expense related to common stock awards issued under equity incentive plan $ 312 In the three months ended March 31, 2020, we issued 17,534 shares of common stock, vested at issuance, to a consultant at a grant date fair value of $1.11 per share and recognized $0.1 million of expense for shares of common stock vesting during the period. Stock options granted in the three months ended March 31, 2020, each vest and become exercisable in annual installments ending four years from the date of grant and were valued using methods and assumptions comparable to those for our 2019 stock option grants. Stock option activity for the three months ended March 31, 2020, follows. Shares Under Options Weighted Average Exercise Price Weighted Average Grant Date Fair Value Weighted Average Remaining Contractual Life (Years) Outstanding at December 31, 2019 996,009 $ 3.23 8.1 Granted 653,004 1.22 $ 0.73 10.0 Forfeited (125,173 ) 4.74 7.2 Outstanding at December 31 1,523,840 $ 2.24 8.8 Restricted stock unit (RSU) activity for the three months ended March 31, 2020, follows. RSU Shares Issued to Employees Unrecognized Stock Compensation (in thousands) Weighted Average Expense Period (Years) Nonvested at December 31, 2019 1,148,062 $ 377 1.4 Cancelled (625,000 ) - Forfeited (1) (175,000 ) (142 ) Expensed (2) - (122 ) Nonvested at March 31, 2020 (3) 348,062 $ 113 1.2 (1) We reversed $0.1 million of expense recognized prior to January 1, 2020 on forfeited RSU shares. (2) We expensed $0.1 million related to recognition of the unrecognized compensation associated with the cancelled RSU shares. (3) The shares subject to the RSUs vest based upon a vesting price equal to the volume weighted average trading price of our common stock over sixty-five consecutive trading days. Subject to a minimum service period, as described in the next sentence, the RSU shares vest as to (i) 34,806 shares on the date the vesting price equals or exceeds $5.00 per share (ii) 104,419 shares the date the vesting price equals or exceeds $10.00 per share and (iii) 208,837 shares the date the vesting price equals or exceeds $15.00 per share. Vesting on the RSU shares occurs the later of the one-year anniversary of the grant and the date the shares reach the vesting price indicated in the preceding sentence. The RSUs expire on the fifth anniversary of each grant at dates ranging through August 2024. In the three months ended March 31, 2020, warrants for the purchase of up to 265,000 shares of common stock ($5.25 per share exercise price) expired.

INCOME TAXES

INCOME TAXES	3 Months Ended
	Mar. 31, 2020
INCOME TAXES [Abstract]
INCOME TAXES	NOTE 11. INCOME TAXES Our tax expense for the three months ended March 31, 2020 and 2019, differs from the tax expense computed by applying the U.S. statutory tax rate to net loss from continuing operations before income taxes as no tax benefits were recorded for tax losses generated in the U.S. As of March 31, 2020, we had deferred tax assets primarily related to U.S. federal and state tax loss carryforwards. We provided a full valuation allowance against our deferred tax assets as future realization of such assets is not more likely than not to occur. Based on an analysis of tax positions taken on income tax returns filed, we have determined no material liabilities related to uncertain income tax positions exist. Although we believe the amounts reflected in our tax returns substantially comply with applicable U.S. federal, state, and foreign tax regulations, the respective taxing authorities may take contrary positions based on their interpretation of the law. A tax position successfully challenged by a taxing authority could result in an adjustment to our provision or benefit for income taxes in the period in which a final determination is made. On March 27, 2020, the Coronavirus Aid, Relief and Economic Security Act (CARES) was signed into law in the U.S. The act, among other things, includes provisions relating to refundable payroll tax credits, deferment of employer social security payments, net operating loss carryback periods, alternative minimum tax credit refunds and modifications to the net interest deduction limitations. Some of these tax provisions are expected to be effective retroactively for years ending before the date of enactment. Except for the impact of the loan we received under the act, see Note 18, we do not anticipate that the act will have a material impact on our financial position, results of operations or cash flows.

DISCONTINUED OPERATIONS

DISCONTINUED OPERATIONS	3 Months Ended
	Mar. 31, 2020
DISCONTINUED OPERATIONS [Abstract]
DISCONTINUED OPERATIONS	NOTE 12. DISCONTINUED OPERATIONS In July 2017, we completed the sale of the assets of Healthy Natural (HN). The selling price was subject to adjustment if the estimated closing working capital with respect to the assets sold and the liabilities assumed was different than the actual closing working capital for those assets and liabilities. The calculation of working capital was disputed. The net gain on sale recognized in 2017 was based on an estimated working capital adjustment. During the three months ended March 31, 2019, the estimated working capital adjustment increased from $0.3 million to $0.5 million when we finalized the adjustment with the purchaser of HN. The adjustment to lower the gain on the sale of HN as a result of the change in the estimated working capital adjustment is recorded in discontinued operations in the three months ended March 31, 2019, net of zero tax benefit.

LOSS PER SHARE (EPS)

LOSS PER SHARE (EPS)	3 Months Ended
	Mar. 31, 2020
LOSS PER SHARE (EPS) [Abstract]
LOSS PER SHARE (EPS)	NOTE 13. LOSS PER SHARE (EPS) Basic EPS is calculated under the two-class method under which all earnings (distributed and undistributed) are allocated to each class of common stock and participating securities based on their respective rights to receive dividends. Our outstanding convertible preferred stock are considered participating securities as the holders may participate in undistributed earnings with holders of common shares and are not obligated to share in our net losses. Diluted EPS is computed by dividing the net income attributable to RiceBran Technologies common shareholders by the weighted average number of common shares outstanding during the period increased by the number of additional common shares that would have been outstanding if the impact of assumed exercises and conversions is dilutive. The dilutive effects of outstanding options, warrants, nonvested shares and restricted stock units that vest solely on the basis of a service condition are calculated using the treasury stock method. The dilutive effects of the outstanding preferred stock are calculated using the if-converted method. Below are reconciliations of the numerators and denominators in the EPS computations. Three Months Ended March 31 2020 2019 NUMERATOR (in thousands): Basic and diluted - loss from continuing operations $ (3,033 ) $ (3,011 ) DENOMINATOR: Basic EPS - weighted average number of common shares outstanding 39,963,155 29,347,318 Effect of dilutive securities outstanding - - Diluted EPS - weighted average number of shares outstanding 39,963,155 29,347,318 Number of shares of common stock which could be purchased with weighted average outstanding securities not included in diluted EPS because effect would be antidilutive: Stock options 1,240,460 1,061,926 Warrants 406,695 10,020,616 Convertible preferred stock 213,523 259,075 Weighted average number of shares of common stock issuable upon vesting of restricted stock units 1,035,425 1,215,000 Weighted average number of nonvested shares of common stock not included in diluted EPS because effect would be antidilutive 116,528 1,044,709 The impacts of potentially dilutive securities outstanding at March 31, 2020 and 2019, were not included in the calculation of diluted EPS for the three months ended March 31, 2020 and 2019 because to do so would be anti-dilutive. Those securities listed in the table above which remain outstanding, could potentially dilute EPS in the future.

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS	3 Months Ended
	Mar. 31, 2020
FAIR VALUE MEASUREMENTS [Abstract]
FAIR VALUE MEASUREMENTS	NOTE 14. FAIR VALUE MEASUREMENTS The fair value of cash and cash equivalents, restricted cash, accounts and other receivables and accounts payable approximates their carrying value due to shorter maturities. As of March 31, 2020, the fair values of our debt, operating lease liabilities and finance lease liabilities approximated their carrying values, based on current market rates for similar debt and leases with similar maturities (Level 3 measurements).

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	3 Months Ended
	Mar. 31, 2020
COMMITMENTS AND CONTINGENCIES [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 15. COMMITMENTS AND CONTINGENCIES Employment Contracts and Severance Payments In the normal course of business, we periodically enter into employment agreements which incorporate indemnification provisions. While the maximum amount to which we may be exposed under such agreements cannot be reasonably estimated, we maintain insurance coverage, which we believe will effectively mitigate our obligations under these indemnification provisions. No amounts have been recorded in our financial statements with respect to any obligations under such agreements. We have employment contracts with certain officers and key management that include provisions for potential severance payments in the event of without-cause terminations or terminations under certain circumstances after a change in control. In addition, vesting of outstanding nonvested equity grants would accelerate following a change in control. Legal Matters From time to time we are involved in litigation incidental to the conduct of our business. These matters may relate to employment and labor claims, patent and intellectual property claims, claims of alleged non-compliance with contract provisions and claims related to alleged violations of laws and regulations. When applicable, we record accruals for contingencies when it is probable that a liability will be incurred and the amount of loss can be reasonably estimated. While the outcome of lawsuits and other proceedings against us cannot be predicted with certainty, in the opinion of management, individually or in the aggregate, no such lawsuits are expected to have a material effect on our financial position or results of operations. Defense costs are expensed as incurred and are included in professional fees.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	3 Months Ended
	Mar. 31, 2020
RELATED PARTY TRANSACTIONS [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 16. RELATED PARTY TRANSACTIONS Our director, Ari Gendason, is an employee and senior vice president and chief investment officer of Continental Grain Company (CGC). As of the date of this filing, CGC owns approximately 26.6% of our outstanding common stock. We have a greed that in connection with each annual or special meeting of our shareholders at which members of our board of directors are to be elected, or any written consent of our shareholders pursuant to which members of the board of directors are to be elected, CGC shall have the right to designate one nominee to our board of directors. exercisable into 1,003,344 shares of common stock for $2.99 per share, in a private placement. The prefunded warrant had an exercise price of $0.01 per share and was immediately exercisable; however, we had to obtain approval from our shareholders before the holder could exercise the prefunded warrant to the extent such exercise would result in the holder owning in excess of 19.99% of our common shares outstanding. The holder exercised the entire prefunded warrant automatically when our shareholders approved the exercise in June 2019.

TRANSACTIONS WITH EMPLOYEES

TRANSACTIONS WITH EMPLOYEES	3 Months Ended
	Mar. 31, 2020
TRANSACTIONS WITH EMPLOYEES [Abstract]
TRANSACTIONS WITH EMPLOYEES	NOTE 17. TRANSACTIONS WITH EMPLOYEES During the three months ended March 31, 2019, we paid $1.4 million to entities owned by our former employee, Wayne Wilkison. As of March 31, 2020, and December 31, 2019, no amounts were owed to these entities.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	3 Months Ended
	Mar. 31, 2020
SUBSEQUENT EVENTS [Abstract]
SUBSEQUENT EVENTS	NOTE 18. SUBSEQUENT EVENTS In April 2020, we were approved for a $1.8 million SBA Payroll Protection Program loan as provided for in CARES. Under certain conditions, the loan and accrued interest are forgivable after eight weeks as long as we use the loan proceeds for eligible purposes, including payroll, benefits, rent and utilities, and maintains payroll levels. The amount of loan forgiveness will be reduced if we terminate employees or reduce salaries during the eight-week period. The unforgiven portion of the loan is payable over two years at an interest rate of 1%, with a deferral of payments for the first six months. We intend to use the proceeds for purposes consistent with the program. While we currently believe that our use of the loan proceeds will meet the conditions for forgiveness of the loan, we cannot assure that we will be eligible for forgiveness of the loan, in whole or in part.

BASIS OF PRESENTATION (Policies

BASIS OF PRESENTATION (Policies)	3 Months Ended
	Mar. 31, 2020
BASIS OF PRESENTATION [Abstract]
Basis of Presentation	In the opinion of management, the accompanying unaudited condensed consolidated financial statements (interim financial statements) of RiceBran Technologies and its subsidiaries were prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) and the rules and regulations of the Securities and Exchange Commission (SEC) for reporting on Form 10-Q; therefore, they do not include all of the information and notes required by GAAP for complete financial statements. The interim financial statements contain all adjustments necessary to present fairly the interim results of operations, financial position and cash flows for the periods presented of a normal and recurring nature necessary to present fairly the interim results of operations, financial position and cash flows for the periods presented. These interim financial statements should be read in conjunction with the consolidated audited financial statements and notes thereto in our Annual Report on Form 10-K for the year ended December 31, 2019, which included all disclosures required by generally accepted accounting principles. The results reported in these interim financial statements are not necessarily indicative of the results to be expected for the full fiscal year, or any other future period, and have been prepared based on the realization of assets and the satisfaction of liabilities in the normal course of business.

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	3 Months Ended
	Mar. 31, 2020
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]
Recent Accounting Standards Not Yet Adopted	Recent accounting standards not yet adopted The following discusses the accounting standard(s) not yet adopted that will, or are expected to, result in a significant change in practice and/or have a significant financial impact on us. In June 2016, the Financial Accounting Standards Board (FASB) issued guidance ASU No. 2016-13 Financial Instruments—Credit Losses (Topic 326) Measurement of Credit Losses on Financial Instruments
Recently Adopted Accounting Standards	Recently adopted accounting standards In December 2019, the FASB issued guidance ASU No. 2019-12 - Income Taxes implifying the Accounting for Income Taxes
Reclassifications	Reclassifications

ACQUISITION (Tables)

ACQUISITION (Tables)	3 Months Ended
	Mar. 31, 2020
MGI Grain Processing LLC [Member]
Business Acquisition [Line Items]
Pro Forma Financial Information	The following table provides unaudited pro forma information for the three months ended March 31, 2019, as if the MGI acquisition had occurred January 1, 2019. Revenues (in thousands) $ 7,506 Loss from continuing operations (in thousands) $ (2,736 ) Loss per share - continuing operations $ (0.09 ) Weighted average number of common shares outstanding - basic and diluted 29,347,318

ACCOUNTS RECEIVABLE AND REVEN_2

ACCOUNTS RECEIVABLE AND REVENUES (Tables)	3 Months Ended
	Mar. 31, 2020
ACCOUNTS RECEIVABLE AND REVENUES [Abstract]
Concentrations of Risk	Revenues and accounts receivable from significant customers (customers with revenue or accounts receivable in excess of 10% of consolidated totals) are stated below as a percent of consolidated totals. Customer A B C D % of revenue, three months ended March 31, 2020 8 % 17 % 8 % 2 % % of revenue, three months ended March 31, 2019 10 % 18 % 10 % - % % of accounts receivable, as of March 31, 2020 9 % 25 % 13 % 4 % % of accounts receivable, as of December 31, 2019 10 % 31 % - % 10 %
Revenues by Product Line	The following table presents revenues by product line (in thousands). Three Months Ended March 31, 2020 2019 Food $ 6,192 $ 4,747 Animal nutrition 2,138 1,617 Revenues $ 8,330 $ 6,364

INVENTORIES (Tables)

INVENTORIES (Tables)	3 Months Ended
	Mar. 31, 2020
INVENTORIES [Abstract]
Components of Inventories	The following table details the components of inventories (in thousands). March 31, December 31, Finished goods $ 1,763 $ 698 Raw materials 20 90 Packaging 133 110 Inventories $ 1,916 $ 898

LEASES (Tables)

LEASES (Tables)	3 Months Ended
	Mar. 31, 2020
LEASES [Abstract]
Components of Lease Expense	The components of lease expense and cash flows from leases (amounts in thousands) follow. Three Months Ended March 31, 2020 2019 Finance lease cost: Amortization of right-of use assets, included in cost of goods sold $ 21 $ 4 Interest on lease liabilities 4 2 Operating lease cost, included in selling, general and administrative expenses: Fixed leases cost 130 130 Variable lease cost 15 32 Short-term lease cost 3 9 Total lease cost $ 173 $ 177 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from finance leases $ 4 $ 2 Operating cash flows from operating leases $ 130 $ 130 Financing cash flows from finance leases $ 26 $ 11
Remaining Lease Term and Discount Rate	The remaining terms of our leases and the discount rates used in the calculation of the fair value of our leases as of March 31, 2020, follows. Operating Leases Finance Leases Remaining leases terms (in years) 3.6-12.9 0.8-4.3 Weighted average remaining lease terms (in years) 7.5 3.1 Discount rates 6.3%-9.0 % 4.3%-6.0 % Weighted average discount rate 7.6 % 5.8 %
Maturities of Lease Liabilities	Maturities of lease liabilities as of March 31, 2020, follows (in thousands). Operating Finance 2020 (nine months ended December 31, 2020) 346 85 2021 536 91 2022 548 68 2023 528 38 2024 428 11 Thereafter 1,469 - Total lease payments 3,855 293 Amounts representing interest (996 ) (27 ) Present value of lease obligations $ 2,859 $ 266

DEBT (Tables)

DEBT (Tables)	3 Months Ended
	Mar. 31, 2020
DEBT [Abstract]
Dues Under Factoring Agreement	Due under factoring agreement consists of the following (in thousands). March 31, 2020 December 31, Borrowings outstanding $ 2,449 $ 1,989 Debt issuance costs, net (143 ) (166 ) Due under factoring agreement $ 2,306 $ 1,823
Long-term Debt	Long-term debt consists of the following (in thousands). March 31, December 31, Equipment notes - Initially recorded in November 2018, in the acquisition of Golden Ridge, at the present value of future payments using a discount rate of 4.8%, which we determined approximated the market rate for similar debt with similar maturities as of the date of acquisition. Payable in monthly installments. Expire at dates ranging through 2022. $ 56 $ 62 Equipment note - Dated December 2019. Due in monthly installments through December 2024. Interest accrues at the effective discount rate of 9.3%. 38 39 Total long term debt $ 94 $ 101

EQUITY, SHARE-BASED COMPENSAT_2

EQUITY, SHARE-BASED COMPENSATION AND WARRANTS (Tables)	3 Months Ended
	Mar. 31, 2020
EQUITY, SHARE-BASED COMPENSATION AND WARRANTS [Abstract]
Equity Activity	A summary of equity activity for the three months ended March 31, 2020 and March 31, 2019, follows (in thousands, except share amounts). Shares Preferred Series G Common Preferred Stock Common Accumulated Equity Balance, December 31, 2019 225 40,074,483 $ 112 $ 318,811 $ (287,180 ) $ 31,743 Common stock awards under equity incentive plans - 17,534 - 312 - 312 Net loss - - - - (3,033 ) (3,033 ) Balance, March 31, 2020 225 40,092,017 $ 112 $ 319,123 $ (290,213 ) $ 29,022 Shares Preferred Common Preferred Common Stock Accumulated Equity Balance, December 31, 2018 405 29,098,207 $ 201 $ 296,739 $ (273,229 ) $ 23,711 Proceeds from sale of common stock and prefunded warrant, net of costs - 3,046,668 - 11,593 - 11,593 Common stock awards under equity incentive plans - 36,881 - 364 - 364 Exercise of common stock warrants - 600,000 - 1,980 - 1,980 Conversion of preferred stock into common stock (180 ) 170,818 (89 ) 89 - - Exercise of common stock options - 77,078 - 60 - 60 Other - - - 28 - 28 Net loss - - - - (3,227 ) (3,227 ) Balance, March 31, 2019 225 33,029,652 $ 112 $ 310,853 $ (276,456 ) $ 34,509
Share-based Compensation by Type of Award	Share-based compensation by type of award for the three months ended March 31, 2020, follows (in thousands). Common stock, vested at issuance and nonvested at issuance $ 105 Stock options 85 Restricted stock units 122 Compensation expense related to common stock awards issued under equity incentive plan $ 312
Stock Option Activity	Stock option activity for the three months ended March 31, 2020, follows. Shares Under Options Weighted Average Exercise Price Weighted Average Grant Date Fair Value Weighted Average Remaining Contractual Life (Years) Outstanding at December 31, 2019 996,009 $ 3.23 8.1 Granted 653,004 1.22 $ 0.73 10.0 Forfeited (125,173 ) 4.74 7.2 Outstanding at December 31 1,523,840 $ 2.24 8.8
RSU Activity	Restricted stock unit (RSU) activity for the three months ended March 31, 2020, follows. RSU Shares Issued to Employees Unrecognized Stock Compensation (in thousands) Weighted Average Expense Period (Years) Nonvested at December 31, 2019 1,148,062 $ 377 1.4 Cancelled (625,000 ) - Forfeited (1) (175,000 ) (142 ) Expensed (2) - (122 ) Nonvested at March 31, 2020 (3) 348,062 $ 113 1.2 (1) We reversed $0.1 million of expense recognized prior to January 1, 2020 on forfeited RSU shares. (2) We expensed $0.1 million related to recognition of the unrecognized compensation associated with the cancelled RSU shares. (3) The shares subject to the RSUs vest based upon a vesting price equal to the volume weighted average trading price of our common stock over sixty-five consecutive trading days. Subject to a minimum service period, as described in the next sentence, the RSU shares vest as to (i) 34,806 shares on the date the vesting price equals or exceeds $5.00 per share (ii) 104,419 shares the date the vesting price equals or exceeds $10.00 per share and (iii) 208,837 shares the date the vesting price equals or exceeds $15.00 per share. Vesting on the RSU shares occurs the later of the one-year anniversary of the grant and the date the shares reach the vesting price indicated in the preceding sentence. The RSUs expire on the fifth anniversary of each grant at dates ranging through August 2024.

LOSS PER SHARE (EPS) (Tables)

LOSS PER SHARE (EPS) (Tables)	3 Months Ended
	Mar. 31, 2020
LOSS PER SHARE (EPS) [Abstract]
Reconciliations of Numerators and Denominators in EPS Computations	Below are reconciliations of the numerators and denominators in the EPS computations. Three Months Ended March 31 2020 2019 NUMERATOR (in thousands): Basic and diluted - loss from continuing operations $ (3,033 ) $ (3,011 ) DENOMINATOR: Basic EPS - weighted average number of common shares outstanding 39,963,155 29,347,318 Effect of dilutive securities outstanding - - Diluted EPS - weighted average number of shares outstanding 39,963,155 29,347,318 Number of shares of common stock which could be purchased with weighted average outstanding securities not included in diluted EPS because effect would be antidilutive: Stock options 1,240,460 1,061,926 Warrants 406,695 10,020,616 Convertible preferred stock 213,523 259,075 Weighted average number of shares of common stock issuable upon vesting of restricted stock units 1,035,425 1,215,000 Weighted average number of nonvested shares of common stock not included in diluted EPS because effect would be antidilutive 116,528 1,044,709

BUSINESS (Details)

BUSINESS (Details)	Mar. 31, 2020Location
BUSINESS [Abstract]
Number of locations	4
Number of locations in California	2
Number of locations in Louisiana	1

ACQUISITION, MGI (Details)

ACQUISITION, MGI (Details) - MGI Grain Processing LLC [Member] $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2019USD ($)$ / sharesshares
Business Acquisition, Pro Forma Information [Abstract]
Revenues	$ 7,506
Loss from continuing operations	$ (2,736)
Loss per share - continuing operations (in dollars per share) | $ / shares	$ (0.09)
Weighted average number of common shares outstanding - Basic and Diluted (in shares) | shares	29,347,318

CASH AND CASH EQUIVALENTS (Deta

CASH AND CASH EQUIVALENTS (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019	Mar. 31, 2019	Dec. 31, 2018
Cash and Cash Equivalents [Abstract]
Cash and cash equivalents	$ 5,517	$ 8,444	$ 13,278	$ 7,044
Money Market Funds [Member]
Cash and Cash Equivalents [Abstract]
Cash and cash equivalents	$ 4,000

ACCOUNTS RECEIVABLE AND REVEN_3

ACCOUNTS RECEIVABLE AND REVENUES (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Concentration of Credit Risk [Abstract]
Revenues	$ 8,330	$ 6,364
Unearned revenue	0		$ 12
Maximum [Member]
Concentration of Credit Risk [Abstract]
Unearned revenue	100
Operating Segments [Member] | Food [Member]
Concentration of Credit Risk [Abstract]
Revenues	6,192	4,747
Operating Segments [Member] | Animal Nutrition [Member]
Concentration of Credit Risk [Abstract]
Revenues	$ 2,138	$ 1,617
Customer A [Member] | Revenue [Member] | Customer Concentration Risk [Member]
Concentration of Credit Risk [Abstract]
Concentration risk, percentage	8.00%	10.00%
Customer A [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]
Concentration of Credit Risk [Abstract]
Concentration risk, percentage	9.00%		10.00%
Customer B [Member] | Revenue [Member] | Customer Concentration Risk [Member]
Concentration of Credit Risk [Abstract]
Concentration risk, percentage	17.00%	18.00%
Customer B [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]
Concentration of Credit Risk [Abstract]
Concentration risk, percentage	25.00%		31.00%
Customer C [Member] | Revenue [Member] | Customer Concentration Risk [Member]
Concentration of Credit Risk [Abstract]
Concentration risk, percentage	8.00%	10.00%
Customer C [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]
Concentration of Credit Risk [Abstract]
Concentration risk, percentage	13.00%		0.00%
Customer D [Member] | Revenue [Member] | Customer Concentration Risk [Member]
Concentration of Credit Risk [Abstract]
Concentration risk, percentage	2.00%	0.00%
Customer D [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]
Concentration of Credit Risk [Abstract]
Concentration risk, percentage	4.00%		10.00%

INVENTORIES (Details)

INVENTORIES (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Inventories [Abstract]
Finished goods	$ 1,763	$ 698
Raw materials	20	90
Packaging	133	110
Inventories	$ 1,916	$ 898

LEASES (Details)

LEASES (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Finance lease cost [Abstract]
Amortization of right-of use assets, included in cost of goods sold	$ 21	$ 4
Interest on lease liabilities	4	2
Operating lease cost, included in selling, general and administrative expenses [Abstract]
Fixed leases cost	130	130
Variable lease cost	15	32
Short-term lease cost	3	9
Total lease cost	173	177
Cash paid for amounts included in the measurement of lease liabilities [Abstract]
Operating cash flows from finance leases	4	2
Operating cash flows from operating leases	130	130
Financing cash flows from finance leases	26	$ 11
Finance lease right-of-use-assets, net	$ 300
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]	us-gaap:PropertyPlantAndEquipmentNet
Finance lease right-of-use-assets, original cost	$ 400
Operating Leases [Abstract]
Weighted average remaining lease terms (in years)	7 years 6 months
Weighted average discount rate	7.60%
Finance Leases [Abstract]
Weighted average remaining lease terms (in years)	3 years 1 month 6 days
Weighted average discount rate	5.80%
Maturities of Operating Lease Liabilities [Abstract]
2020 (nine months ended December 31, 2020)	$ 346
2021	536
2022	548
2023	528
2024	428
Thereafter	1,469
Total lease payments	3,855
Amounts representing interest	(996)
Present value of lease obligations	2,859
Maturities of Finance Lease Liabilities [Abstract]
2020 (nine months ended December 31, 2020)	85
2021	91
2022	68
2023	38
2024	11
Thereafter	0
Total lease payments	293
Amounts representing interest	(27)
Present value of lease obligations	$ 266
Minimum [Member]
Operating Leases [Abstract]
Remaining leases terms (in years)	3 years 7 months 6 days
Discount rate	6.30%
Finance Leases [Abstract]
Remaining leases terms (in years)	9 months 18 days
Discount rate	4.30%
Maximum [Member]
Operating Leases [Abstract]
Remaining leases terms (in years)	12 years 10 months 24 days
Discount rate	9.00%
Finance Leases [Abstract]
Remaining leases terms (in years)	4 years 3 months 18 days
Discount rate	6.00%

DEBT (Details)

DEBT (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended
	Oct. 31, 2019	Mar. 31, 2020	Dec. 31, 2019
Due under Factoring Agreement [Abstract]
Due under factoring agreement		$ 2,306	$ 1,823
Long-term Debt [Abstract]
Total long-term debt		$ 94	101
Financing Agreement [Member]
Debt Instruments [Abstract]
Maturity date		Nov. 30, 2020
Financing Agreement [Member] | Minimum [Member]
Debt Instruments [Abstract]
Long term debt interest rate		4.70%
Financing Agreement [Member] | Maximum [Member]
Debt Instruments [Abstract]
Long term debt interest rate		5.50%
Factoring Agreement [Member]
Due under Factoring Agreement [Abstract]
Borrowing outstanding		$ 2,449	1,989
Debt issuance costs, net		(143)	(166)
Due under factoring agreement		2,306	1,823
Factoring Agreement [Member] | Line of Credit [Member]
Debt Instruments [Abstract]
Line of credit facility, maximum borrowing capacity		$ 7,000
Line of credit facility, initial term		2 years
Facility fee, amount	$ 200
Percentage of funding fee		0.50%
Interest and fees expense		$ 100
Fees incurred averaged percentage		3.90%
Interest averaged percentage		1.70%
Outstanding borrowings average amount		$ 1,100
Factoring Agreement [Member] | Line of Credit [Member] | Minimum [Member]
Debt Instruments [Abstract]
Line of credit facility, recurring fee	5.50%
Factoring Agreement [Member] | Line of Credit [Member] | Maximum [Member]
Debt Instruments [Abstract]
Amortization of debt issuance costs		$ 100
Equipment Notes, November 2018 [Member] | Notes Payable [Member]
Debt Instruments [Abstract]
Long term debt interest rate		4.80%
Maturity date		Dec. 31, 2022
Long-term Debt [Abstract]
Total long-term debt		$ 56	62
Equipment Notes, December 2019 [Member] | Notes Payable [Member]
Debt Instruments [Abstract]
Long term debt interest rate		9.30%
Maturity date		Dec. 31, 2024
Long-term Debt [Abstract]
Total long-term debt		$ 38	$ 39

EQUITY, SHARE-BASED COMPENSAT_3

EQUITY, SHARE-BASED COMPENSATION AND WARRANTS, Summary of Equity Activity (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Balance	$ 31,743	$ 23,711
Balance (in shares)	40,074,483
Proceeds from sale of common stock and prefunded warrant, net of costs		11,593
Common stock awards under equity incentive plans	$ 312	364
Exercise of common stock warrants		1,980
Conversion of preferred stock into common stock		0
Exercise of common stock options		60
Other		28
Net loss	(3,033)	(3,227)
Balance	$ 29,022	34,509
Balance (in shares)	40,092,197
Preferred Stock [Member]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Balance	$ 112	201
Proceeds from sale of common stock and prefunded warrant, net of costs		0
Common stock awards under equity incentive plans	0	0
Exercise of common stock warrants		0
Conversion of preferred stock into common stock		(89)
Exercise of common stock options		0
Other		0
Net loss	0	0
Balance	$ 112	$ 112
Preferred Stock [Member] | Series G Preferred Stock [Member]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Balance (in shares)	225	405
Proceeds from sale of common stock and prefunded warrant, net of costs (in shares)		0
Common stock awards under equity incentive plans (in shares)	0	0
Exercise of common stock warrants (in shares)		0
Conversion of preferred stock into common stock (in shares)		(180)
Exercise of common stock options (in shares)		0
Other (in shares)		0
Balance (in shares)	225	225
Common Stock [Member]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Balance	$ 318,811	$ 296,739
Balance (in shares)	40,074,483	29,098,207
Proceeds from sale of common stock and prefunded warrant, net of costs		$ 11,593
Proceeds from sale of common stock and prefunded warrant, net of costs (in shares)		3,046,668
Common stock awards under equity incentive plans	$ 312	$ 364
Common stock awards under equity incentive plans (in shares)	17,534	36,881
Exercise of common stock warrants		$ 1,980
Exercise of common stock warrants (in shares)		600,000
Conversion of preferred stock into common stock		$ 89
Conversion of preferred stock into common stock (in shares)		170,818
Exercise of common stock options		$ 60
Exercise of common stock options (in shares)		77,078
Other		$ 28
Other (in shares)		0
Net loss	$ 0	$ 0
Balance	$ 319,123	$ 310,853
Balance (in shares)	40,092,017	33,029,652
Accumulated Deficit [Member]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Balance	$ (287,180)	$ (273,229)
Proceeds from sale of common stock and prefunded warrant, net of costs		0
Common stock awards under equity incentive plans	0	0
Exercise of common stock warrants		0
Conversion of preferred stock into common stock		0
Exercise of common stock options		0
Other		0
Net loss	(3,033)	(3,227)
Balance	$ (290,213)	$ (276,456)

EQUITY, SHARE-BASED COMPENSAT_4

EQUITY, SHARE-BASED COMPENSATION AND WARRANTS, Sales Agreement (Details) - At-the-Market Offering [Member] $ in Millions	Mar. 30, 2020USD ($)
Share Based Compensation Arrangement By Share Based Payment Award Information [Abstract]
Deferred offering costs, legal expenses and other costs	$ 0.1
Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award Information [Abstract]
Aggregate offering price of common stock	$ 6

EQUITY, SHARE-BASED COMPENSAT_5

EQUITY, SHARE-BASED COMPENSATION AND WARRANTS, Share-Based Compensation by Type of Award (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Share-based compensation expense [Abstract]
Compensation expense related to common stock awards issued under equity incentive plan	$ 312
Common Stock [Member]
Common Stock Issued under Equity Incentive Plans [Abstract]
Shares issued (in shares)	17,534	36,881
Common Stock [Member] | Consultant [Member]
Share-based compensation expense [Abstract]
Compensation expense related to common stock awards issued under equity incentive plan	$ 100
Common Stock Issued under Equity Incentive Plans [Abstract]
Shares issued (in shares)	17,534
Grant date fair value (in dollars per share)	$ 1.11
Common Stock, Vested at Issuance and Nonvested at Issuance [Member]
Share-based compensation expense [Abstract]
Compensation expense related to common stock awards issued under equity incentive plan	$ 105
Stock Options [Member]
Share-based compensation expense [Abstract]
Compensation expense related to common stock awards issued under equity incentive plan	85
Restricted Stock Units [Member]
Share-based compensation expense [Abstract]
Compensation expense related to common stock awards issued under equity incentive plan	$ 122

EQUITY, SHARE-BASED COMPENSAT_6

EQUITY, SHARE-BASED COMPENSATION AND WARRANTS, Options (Details) - Stock Options [Member] - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Line Items]
Options exercisable period	4 years
Shares Under Options, Outstanding [Roll Forward]
Outstanding at beginning of period (in shares)	996,009
Granted (in shares)	653,004
Forfeited (in shares)	(125,173)
Outstanding at end of period (in shares)	1,523,840	996,009
Options, Weighted Average Exercise Price [Roll Forward]
Outstanding at beginning of period (in dollars per share)	$ 3.23
Granted (in dollars per share)	1.22
Forfeited (in dollars per share)	4.74
Outstanding at end of period (in dollars per share)	2.24	$ 3.23
Options, Weighted Average Grant Date Fair Value [Abstract]
Granted (in dollars per share)	$ 0.73
Options, Weighted Average Remaining Contractual Life [Abstract]
Outstanding, weighted average remaining contractual life	8 years 9 months 18 days	8 years 1 month 6 days
Granted	10 years
Forfeited	7 years 2 months 12 days

EQUITY, SHARE-BASED COMPENSAT_7

EQUITY, SHARE-BASED COMPENSATION AND WARRANTS, Restricted Stock Units (Details) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended		12 Months Ended
		Mar. 31, 2020		Dec. 31, 2019
Weighted Average Remaining Vesting and Expense Period [Abstract]
Share-based compensation expense recognized		$ 312
Restricted Stock Units [Member]
Weighted Average Remaining Vesting and Expense Period [Abstract]
Share-based compensation expense reversal on forfeited shares		100
Share-based compensation expense recognized		$ 122
Restricted Stock Units [Member] | Minimum [Member]
Weighted Average Remaining Vesting and Expense Period [Abstract]
Award vesting period		1 year
Restricted Stock Units [Member] | Maximum [Member]
Weighted Average Remaining Vesting and Expense Period [Abstract]
Award vesting period		5 years
Restricted Stock Units [Member] | Employees [Member]
Restricted Stock Award Activity, Number [Roll Forward]
Beginning balance, Nonvested (in shares)		1,148,062
Cancelled (in shares)		(625,000)
Forfeited (in shares)	[1]	(175,000)
Ending balance, Nonvested (in shares)		348,062	[2]	1,148,062
Unrecognized Stock Compensation [Abstract]
Unrecognized stock compensation		$ 377
Cancelled		0
Expensed	[3]	(122)
Forfeited	[1]	(142)
Unrecognized stock compensation		$ 113	[2]	$ 377
Weighted Average Remaining Vesting and Expense Period [Abstract]
Weighted average expense period (Years)		1 year 2 months 12 days	[2]	1 year 4 months 24 days
Vesting Price Equals or Exceeds $5.00 [Member] | Restricted Stock Units [Member]
Weighted Average Remaining Vesting and Expense Period [Abstract]
Number of trading days		65 days
Vested (in shares)		34,806
Vesting price (in dollars per share)		$ 5
Vesting Price Equals or Exceeds $10.00 [Member] | Restricted Stock Units [Member]
Weighted Average Remaining Vesting and Expense Period [Abstract]
Vested (in shares)		104,419
Vesting price (in dollars per share)		$ 10
Vesting Price Equals or Exceeds $15.00 [Member] | Restricted Stock Units [Member]
Weighted Average Remaining Vesting and Expense Period [Abstract]
Vested (in shares)		208,837
Vesting price (in dollars per share)		$ 15
[1]	We reversed $0.1 million of expense recognized prior to January 1, 2020 on forfeited RSU shares.
[2]	The shares subject to the RSUs vest based upon a vesting price equal to the volume weighted average trading price of our common stock over sixty-five consecutive trading days. Subject to a minimum service period, as described in the next sentence, the RSU shares vest as to (i) 34,806 shares on the date the vesting price equals or exceeds $5.00 per share (ii) 104,419 shares the date the vesting price equals or exceeds $10.00 per share and (iii) 208,837 shares the date the vesting price equals or exceeds $15.00 per share. Vesting on the RSU shares occurs the later of the one-year anniversary of the grant and the date the shares reach the vesting price indicated in the preceding sentence. The RSUs expire on the fifth anniversary of each grant at dates ranging through August 2024.
[3]	We expensed $0.1 million related to recognition of the unrecognized compensation associated with the cancelled RSU shares.

EQUITY, SHARE-BASED COMPENSAT_8

EQUITY, SHARE-BASED COMPENSATION AND WARRANTS, Warrants (Details) - Warrant [Member] - $5.25 [Member]	1 Months Ended
	Oct. 31, 2019$ / sharesshares
Warrants, Additional Disclosures [Abstract]
Warrants expired (in shares) | shares	(265,000)
Warrants expired, exercise price (in dollars per share) | $ / shares	$ 5.25

DISCONTINUED OPERATIONS (Detail

DISCONTINUED OPERATIONS (Details) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Mar. 31, 2019	Dec. 31, 2018
Healthy Natural [Member]
Healthy Natural (HN) Discontinued Operations [Abstract]
Estimated working capital adjustments	$ 0.5	$ 0.3

LOSS PER SHARE (EPS) (Details)

LOSS PER SHARE (EPS) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
NUMERATOR [Abstract]
Basic and diluted - loss from continuing operations	$ (3,033)	$ (3,011)
DENOMINATOR [Abstract]
Basic EPS - weighted average number of common shares outstanding (in shares)	39,963,155	29,347,318
Effect of dilutive securities outstanding (in shares)	0	0
Diluted EPS - weighted average number of shares outstanding (in shares)	39,963,155	29,347,318
Stock Options [Member]
Antidilutive Securities [Abstract]
Number of shares of common stock which could be purchased with weighted average outstanding securities not included in diluted EPS because effect would be antidilutive (in shares)	1,240,460	1,061,926
Warrants [Member]
Antidilutive Securities [Abstract]
Number of shares of common stock which could be purchased with weighted average outstanding securities not included in diluted EPS because effect would be antidilutive (in shares)	406,695	10,020,616
Convertible Preferred Stock [Member]
Antidilutive Securities [Abstract]
Number of shares of common stock which could be purchased with weighted average outstanding securities not included in diluted EPS because effect would be antidilutive (in shares)	213,523	259,075
Restricted Stock Units [Member]
Antidilutive Securities [Abstract]
Number of shares of common stock which could be purchased with weighted average outstanding securities not included in diluted EPS because effect would be antidilutive (in shares)	1,035,425	1,215,000
Nonvested Shares of Common Stock [Member]
Antidilutive Securities [Abstract]
Number of shares of common stock which could be purchased with weighted average outstanding securities not included in diluted EPS because effect would be antidilutive (in shares)	116,528	1,044,709

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details)	3 Months Ended
	Mar. 31, 2020Nominee$ / shares	Mar. 31, 2019$ / sharesshares
Minimum [Member]
Related Party Transaction Information [Abstract]
Ownership percentage	19.99%
Ari Gendason [Member] | Continental Grain Company [Member]
Related Party Transaction Information [Abstract]
Ownership interest percentage	26.60%
Sale of common stock (in shares) | shares		666,667
Share price (in dollars per share)		$ 3
Exercise price per warrant (in dollars per share)	$ 0.01
Number of nominee for the Board of Directors related party can designate | Nominee	1
Ari Gendason [Member] | Continental Grain Company [Member] | Private Placement [Member]
Related Party Transaction Information [Abstract]
Shares callable by Prefunded Warrant (in shares) | shares		1,003,344
Share price (in dollars per share)		$ 2.99

TRANSACTIONS WITH EMPLOYEES (De

TRANSACTIONS WITH EMPLOYEES (Details) - Wayne Wilkison [Member] - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2020	Dec. 31, 2019
Employee Transaction [Abstract]
Amount paid to related parties	$ 1.4
Amounts payable to entities		$ 0	$ 0

SUBSEQUENT EVENTS (Details)

SUBSEQUENT EVENTS (Details) - Subsequent Event [Member] - PPP Loan [Member] $ in Millions	Apr. 28, 2020USD ($)
SBA Payroll Protection Program Loan [Abstract]
Loan amount	$ 1.8
Interest rate	1.00%